LIFE SCIENCES PENNSYLVANIA for LIFE SCIENCES PENNSYLVANIA
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Science/Technology SCI
Keep legislators apprised of developments/news in the Commonwealth's life sciences ecosystem.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Copyright/Patent/Trademark CPT
Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Insurance INS
Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Medicare/Medicaid MMM
Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Medical/Disease Research/Clinical Labs MED
Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Budget/Appropriations BUD
Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration Life Sciences Pennsylvania supports Federal incentivize investment in the R&D of therapies and cures for rare disorders as well as policies to improve public health and pandemic preparedness including anti-microbial resistance, PAHPA reauthorization, and substance use disorder crisis. H.R. 7384, the Creating Hope Reauthorization Act of 2024 would reauthorize the Rare Pediatric Disease Priority Review Voucher Program (PPRV). The program incentivizes the development of novel therapies to treat pediatric rare diseases. By September of 2024, the Pediatric Priority Review Voucher will expire, and Life Sciences Pennsylvania supports the reauthorization of this crucial legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Taxation/Internal Revenue Code TAX
Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LARA FLYNN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.